109
Participants
Start Date
November 2, 2020
Primary Completion Date
October 26, 2024
Study Completion Date
October 26, 2024
Tabrecta tablets
There was no treatment allocation. Patients administered Tabrecta by prescription that had started before inclusion of the patient into the study were enrolled.
Novartis Investigative Site, Kōnan
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Higashi Okitama
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Okazaki
Novartis Investigative Site, Toyoake
Novartis Investigative Site, Toyota
Novartis Investigative Site, Daisen
Novartis Investigative Site, Hachinohe
Novartis Investigative Site, Sakura
Novartis Investigative Site, Fukui-shi
Novartis Investigative Site, Yoshida-gun
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Ōgaki
Novartis Investigative Site, Higashihiroshima
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Akashi
Novartis Investigative Site, Himeji
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Tsuchiura
Novartis Investigative Site, Tsukuba
Novartis Investigative Site, Kan’onjichō
Novartis Investigative Site, Sakaidechō
Novartis Investigative Site, Takamatsu
Novartis Investigative Site, Fujisawa
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Tsu
Novartis Investigative Site, Yokkaichi
Novartis Investigative Site, Miyakonojō
Novartis Investigative Site, Matsumoto
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Kurashiki
Novartis Investigative Site, Okayama
Novartis Investigative Site, Kishiwada
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Saga
Novartis Investigative Site, Kawaguchi
Novartis Investigative Site, Kumagaya
Novartis Investigative Site, Saitama
Novartis Investigative Site, Saitama
Novartis Investigative Site, Izumo
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Chuo Ku
Novartis Investigative Site, Edogawa City
Novartis Investigative Site, Kiyose
Novartis Investigative Site, Koto Ku
Novartis Investigative Site, Minato
Novartis Investigative Site, Minato Ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Shibuya City
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Tama
Novartis Investigative Site, Toyama
Novartis Investigative Site, Ube
Novartis Investigative Site, Aomori
Novartis Investigative Site, Chiba
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Osaka
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY